◀ Back to NOS3

CRH — NOS3

Text-mined interactions from Literome

Cantarella et al., Br J Pharmacol 2001 : Divergent effects of corticotropin releasing hormone on endothelial cell nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors
Ralph et al., Am J Pathol 2007 (Arthritis...) : CRH enhanced the expression of nitric-oxide synthase ( NOS III ) to promote NO production from CRH-R1alpha expressing cells
Jain et al., Am J Obstet Gynecol 1997 : The relaxation induced by corticotropin releasing factor in aortic rings from nonpregnant rats decreased after deendothelization and treatment with N omega-nitro-L-arginine methyl ester ( a nitric oxide synthase inhibitor ), LY-83,583 ( a guanylate cyclase inhibitor ), or alpha-helical corticotropin releasing factor 9-41 ( a corticotropin releasing factor antagonist )
Raber et al., Brain research. Brain research reviews 1998 (Disease Models, Animal...) : The IFNalpha stimulated release of AVP and CRH appears to be mediated by cyclic GMP production, and this release by IFNalpha and IL-2 may be mediated in part by activation of constitutive nitric oxide synthase
Tomikawa et al., Am J Physiol 1998 (Kidney Failure, Chronic) : CRF significantly decreased endothelial NOS (eNOS) mRNA abundance by 53 % ( P < 0.01 ) and reduced expression of eNOS protein by 42 % ( P < 0.01 ) compared with the controls